Imatinib-induced apoptosis: a possible link to topoisomerase enzyme inhibition
Articles > Article · 2011
Authors: Y. Baran, S. Zencır, Esra ÖZTÜRK YİĞİT, Esra Öztürk, Zeki TOPÇU
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, Journal Indexed in SCI Expanded, International, 2011, vol 36, pp 673-679
DOI: 10.1111/j.1365-2710.2010.01224.x
Summary
What is known and Objective: Imatinib is a specific BCR/ABL inhibitor, commonly used for the treatment of chronic myeloid leukaemia (CML), a hematological malignancy resulting from a chromosomal translocation that generates the BCR/ABL fusion protein. Recent studies showed that the imatinib has cytotoxic and apoptotic effects on many BCR/ABL-negative cancers. Numerous compounds with cytotoxic potential exert their functions by interfering with the DNA topoisomerase. In this study, we examined the effects of imatinib on tumour cell-killing in relation to DNA topoisomerase enzyme inhibition.